Key Highlights

  • OncoSil remains quoted on the ASX and is not suspended, but it consolidated its capital in June 2025 and has raised equity three times since May 2025, including an AUD 8.0 million placement and prospectus in February 2026.
  • The TRIPP-FFX randomised trial met both co-primary endpoints in June 2026, the TGA added the device to the ARTG in May 2026, and the company filed for United States approval via the Humanitarian Device Exemption pathway on 3 July 2026.
  • Reported revenue of about AUD 1.26 million in FY2025 against a net loss near AUD 15.1 million leaves funding as the central risk; the March-quarter cash balance could not be verified because the ASX-hosted Appendix 4C was inaccessible.
  • Manufacturing validation and additional regulatory progress support commercialisation, but recurring revenue remains limited.

After years of regulatory grind and repeated dilution, OncoSil has strung together Australian approval, positive randomised trial data and a United States filing inside three months. The shares have given back ground anyway, on a screener reading no one can verify.

Why the stock is in focus

OncoSil Medical Limited spent much of the past decade defined by what it had not yet achieved. Its single product, a phosphorus-32 brachytherapy device injected directly into pancreatic tumours, held European CE marking for years without producing meaningful revenue, and shareholders funded the wait through repeated raisings and a June 2025 consolidation.

The last few months have looked different. Australian regulatory approval landed in May 2026, a randomised trial reported positive results in June, and a United States filing followed in July. Against that run of news, a single-session pullback invites a closer look at how much has actually changed.

The share-price movement

A TradingView screener of Australian decliners supplied for this series did not capture ASX:OSL at all; the reading attached to the stock is a client-supplied figure showing OncoSil down roughly 3.9 per cent in a single session. That figure is a point-in-time screener reading rather than a verified closing price, and Kalkine has not been able to independently confirm it against official ASX market data.

The stock compounds the difficulty. Snapshots retrieved on 28 July 2026 showed last-traded prices from about AUD 1.17 to AUD 1.45, one with an intraday band of AUD 0.99 to AUD 1.175. They disagree, so none is treated as a closing price. The 52-week range of roughly AUD 0.37 to AUD 2.09 conveys the volatility.

No single confirmed company-specific catalyst was identified for the share-price movement. Nothing negative was released to the market beforehand.

Latest announcement or development

The most consequential recent filing, lodged 3 July 2026, was titled OncoSil Medical Files for FDA Approval. It followed a 9 June announcement that the company was progressing a Humanitarian Device Exemption with the US Food and Drug Administration. The HDE route covers devices for conditions affecting no more than 8,000 Americans a year and, unlike premarket approval, does not require effectiveness to be demonstrated to the usual standard.

July also brought completion of manufacturing validation, Saudi Arabian regulatory approval, an investor presentation and an independent study on dose flexibility. Applications for quotation of securities on 17 and 23 July indicate fresh shares entering the register.

Recent financial and operational performance

Data-provider figures show reported revenue of about AUD 1.26 million for FY2025, against AUD 0.58 million in FY2024 and AUD 0.43 million in FY2023. The net loss widened to roughly AUD 15.1 million from AUD 11.9 million, so improving sales were outpaced by trial, regulatory and commercial spending. These are third-party figures, not numbers read from the audited report.

Operationally the picture is better than the accounts. First treatments were recorded in Portugal and Germany during October 2025 and in the United Kingdom that December, and device production began at a new Sydney facility in December 2025.

Business model and principal assets

OncoSil sells a single-use implantable device rather than a drug. Phosphorus-32 microparticles are delivered under endoscopic ultrasound guidance into unresectable locally advanced pancreatic tumours, alongside gemcitabine-based chemotherapy, with the aim of local tumour control and volume reduction. The commercial model is hospital-by-hospital: each site needs trained endoscopists, nuclear medicine support and a funding pathway.

Regulatory assets underpin the business. BSI granted CE marking, and certification under the EU Medical Device Regulation followed in January 2025, a step the company said removed post-market restrictions requiring local ethics and hospital sign-off before commercial treatments. Australian approval and ARTG inclusion came on 20 May 2026.

Growth opportunities

Germany is the clearest reimbursement opportunity. In October 2024 the Federal Joint Committee (G-BA) issued a directive enabling a randomised trial under the country's coverage-with-evidence-development framework, allowing conditional reimbursement while evidence is gathered. The company later said 120 German hospitals could negotiate a fee for the procedure.

Elsewhere, the TGA decision opens Australia, Saudi approval adds a Gulf market, and the HDE filing could provide a US foothold. A 2 July announcement said OncoSil had been selected for a major European pancreatic cancer study; that document was not readable, so its scale is not described here.

Balance sheet, funding and cash flow

OncoSil has funded itself through the equity market with some regularity: an AUD 8.7 million raise announced in May 2025, a AUD 2 million share purchase plan completed that July, and an AUD 8.0 million raise supported by a prospectus in February 2026. Capital was consolidated on 6 June 2025, and a AUD 1.05 million research and development tax incentive arrived in January 2025.

The March 2026 Appendix 4C was lodged on 28 April, but the ASX-hosted document sits behind an access interstitial and could not be read, so the cash balance and the company's own estimate of quarters of funding available are not stated here. As context only, a FY2025 loss near AUD 15 million implies a burn well above AUD 1 million a month, against which an AUD 8 million raise buys limited runway.

Principal risks

Funding is the first-order risk. A company with roughly AUD 1.3 million of annual revenue and losses more than ten times that will very likely return to the market, and the recent history of consolidation, prospectuses and share purchase plans shows what that has meant for existing holders.

Regulatory risk remains live. Filing for an HDE is not approval, and the FDA can seek further information or decline. The pathway also caps commercial volumes through an annual distribution number mechanism, limiting how large a US business can become. Reimbursement is a separate hurdle in every market.

Execution risk is concentrated in one product, one indication and a specialised procedure. The company also lodged responses to an ASX Aware letter in September 2025 and an ASX query letter in October 2025.

Valuation and investor expectations

With roughly 30.9 million shares on issue after consolidation, OncoSil's market capitalisation sat somewhere between about AUD 36 million and AUD 45 million across the snapshots retrieved, and the spread between them is itself a reason for caution. Prices and multiples change continuously.

Price-to-earnings is not meaningful: the company is loss-making, with earnings per share near negative AUD 0.94 for FY2025, so any P/E figure is an artefact, and EV/EBITDA is unusable with negative EBITDA. On revenue of roughly AUD 1.26 million the implied price-to-sales multiple sits in the low-to-mid thirties. No dividend is paid, free cash flow is negative, and no reliable cash figure was obtainable, so enterprise value is not calculated.

Outlook

The near-term markers are clear enough: the June-quarter Appendix 4C and its cash disclosure, any FDA acceptance or request for information on the HDE submission, the first Australian commercial treatments following ARTG inclusion, and progress on the German coverage-with-evidence study.

On the evidence of its 2026 filings, OncoSil has moved from a company with a device and a hypothesis to one with randomised data, several approvals and a manufacturing base. Whether that converts into revenue at a scale outrunning the cash burn is what the share price is still arguing about.